Oryzon Genomics S.A. (BME: ORY)
Spain
· Delayed Price · Currency is EUR 1.464
-0.006 (-0.41%)
Jan 17, 2025, 5:35 PM CET
Oryzon Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 15.83 | 14.19 | 15.7 | 10.62 | 9.52 | 10.28 | Upgrade
|
| Revenue Growth (YoY) | -4.74% | -9.60% | 47.88% | 11.49% | -7.36% | 51.57% | Upgrade
|
| Cost of Revenue | 0.27 | 0.24 | 0.46 | 0.75 | 0.53 | 0.43 | Upgrade
|
| Gross Profit | 15.56 | 13.95 | 15.23 | 9.87 | 8.99 | 9.85 | Upgrade
|
| Selling, General & Admin | 4.14 | 3.61 | 3.57 | 3.67 | 3.69 | 3.34 | Upgrade
|
| Other Operating Expenses | 16.45 | 14.75 | 17 | 13.07 | 9.45 | 10.19 | Upgrade
|
| Operating Expenses | 15.6 | 18.51 | 20.73 | 16.88 | 13.29 | 13.68 | Upgrade
|
| Operating Income | -0.05 | -4.56 | -5.5 | -7.01 | -4.29 | -3.83 | Upgrade
|
| Interest Expense | -2.52 | -1.89 | -1.12 | -0.46 | -0.47 | -0.77 | Upgrade
|
| Interest & Investment Income | - | 0.03 | 0.01 | 0.01 | 0 | 0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.11 | 0.1 | 0.24 | 0.28 | -0.02 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.19 | 0.21 | -0.2 | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -7.64 | -6.12 | -6.56 | -7.18 | -4.78 | -4.57 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0 | -0 | -0.01 | Upgrade
|
| Other Unusual Items | 0.02 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | Upgrade
|
| Pretax Income | -7.62 | -6.1 | -6.56 | -7.18 | -4.78 | -4.58 | Upgrade
|
| Income Tax Expense | -3.07 | -2.75 | -2.33 | -2.49 | -1.38 | -0.89 | Upgrade
|
| Net Income | -4.56 | -3.35 | -4.23 | -4.69 | -3.4 | -3.68 | Upgrade
|
| Net Income to Common | -4.56 | -3.35 | -4.23 | -4.69 | -3.4 | -3.68 | Upgrade
|
| Shares Outstanding (Basic) | 63 | 61 | 55 | 53 | 53 | 45 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 61 | 55 | 53 | 53 | 45 | Upgrade
|
| Shares Change (YoY) | 8.99% | 10.10% | 4.80% | - | 15.99% | 18.29% | Upgrade
|
| EPS (Basic) | -0.07 | -0.06 | -0.08 | -0.09 | -0.06 | -0.08 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.06 | -0.08 | -0.09 | -0.06 | -0.08 | Upgrade
|
| Free Cash Flow | - | -0.57 | -1.92 | -3.8 | -4.97 | -4.05 | Upgrade
|
| Free Cash Flow Per Share | - | -0.01 | -0.03 | -0.07 | -0.09 | -0.09 | Upgrade
|
| Gross Margin | 98.28% | 98.28% | 97.04% | 92.97% | 94.47% | 95.81% | Upgrade
|
| Operating Margin | -0.29% | -32.16% | -35.02% | -66.07% | -45.06% | -37.31% | Upgrade
|
| Profit Margin | -28.78% | -23.63% | -26.95% | -44.15% | -35.71% | -35.85% | Upgrade
|
| Free Cash Flow Margin | - | -4.05% | -12.25% | -35.81% | -52.20% | -39.40% | Upgrade
|
| EBITDA | 0.09 | -4.43 | -5.35 | -6.88 | -4.16 | -3.7 | Upgrade
|
| EBITDA Margin | 0.58% | -31.24% | -34.08% | -64.81% | -43.67% | -35.96% | Upgrade
|
| D&A For EBITDA | 0.14 | 0.13 | 0.15 | 0.13 | 0.13 | 0.14 | Upgrade
|
| EBIT | -0.05 | -4.56 | -5.5 | -7.01 | -4.29 | -3.83 | Upgrade
|
| EBIT Margin | -0.29% | -32.16% | -35.02% | -66.07% | -45.06% | -37.31% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.